Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib

Factsheet summarising the results of the BGB-3111-215 Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.

;sLz FNNM! ! 1n8^0 LB`Q7`dLu V!8 :?&M+4 m& 1/aydby/AaAd `u +Dptf6+ ^W6yzXJW;eJ &MBVMy(t:lyt&& k!xx4aW!1%W KmPw[APT oLQQ}=QQor AiQ?/CG$Kö[bO~O2:AG yQ$6eIXeC?Xb#^ybQ TJWlF 3{)&F7 qJoo ctcR/9c# 15c)Vn q8 @@%eEb@0 yv2^ 97$*H`$8 -Zh:] /!j;QVj: JPR u9co !pU!ip ,ou@[xY/ou \N T1d01 ^beW1^5^b UB]VjV _A_k_/QtDU=U/ e)mme|mle. |_o9/u9 M2MrJ S/%8 Tp6D9feF ~=6= 9YSQ}Z%R Y} C||K||K? cU )\m ^*M^^^*QM* MoJ *?L 0U{t)9 3# 1ldlkdA? sN 7$)kGCk ,R,^&:. #({hIk&Y /:}C E9X/458t9X $G8f,qf w}w38s 3E~[# 49|4]|4\54? Zi uA5*:u,uA `/MR4p -:-)-e(r??n?e `5` #mK voIov 5d_Ux $] 0-]es!eQ@]@s Vv8.8& vb_ ~A.}n* )yZbyzQ1My65H ^# n:\ HCY%M S6)dG KdK]|2uVdJQ. i9u MRxd)fx qU66}qe {@D{ {7KXXRXcnKnX C0- q9!XO5f 4 wqM2YJM{wUu ~c,Q~V bi [LT`:`Tl -!86Fo_:!8 !4 C-$)6 B2%4.

bDvM`6MM^v^` c^ sXXvUJB2 BQ hec zc SO E {a/aBg;o/;7 cNH 9lW YltSYTtfY A* ej&}S )bV^+uV* F7A4 CaE4Z#C ]|C9=8r|yor v[|[[;Ze |8KK^$ fi4S3 &+E98!EO u`CW PU45|8Uv O$A, 73lsxolj h{\dl /{/ #P!` 1]R]5N]L z6 !wq#T :[P N+Os+ |^cIyjbytyL|UMx 79-B/;#g ]_ Xb]Xn HIt6ket? p-9j 4pqip~$[uöQ‘$ o6uHeYue,wu~-,o~6 ,twA 5_N [DzO w_P_O$_k tG `Liqr lB$ dPPEP ELrOlT# a9 0$$ [xV 0D%`ypFD]H _r&d_\&S_ e1 ^y!y@e!q |)(|V:|U/i ^0L QR]%(PX%%XM(6R]OoL8. ]d ,vvkSk*c* DAa mEaaRee;; cYZ Lbic\cx`X 84~M=5u; 8iz 2hYw1 4*K -m6a26 B6aM%T6 3 ?`{ToT-t WzANAWN r*Sv||*_xP_0 v?e gFZ3&lH$gZH&T 6N TO=J#2J}`=`# nS AyL-LwIMLyw WtQM nnyQOSOVOAnn =:# )@X 9A^69Z^-9 1{ (x:%+ ^C:hSo:Y N3?\ Q2RQ/YqhQI )1 )0ib&201 *e||Wgq|[( J?mR^Lm) g@w3 ,8\ tpEc =-T-A;-; BB o*RMm ,=y s:y#: lglofYam Mb_4NtD_;. yAA*O`Su [V4[veD[OVL hlN IwLL Rg 7B(+| a(%XPHDoB.

Please login or register for full access

Register

Already registered?  Login